187 related articles for article (PubMed ID: 27681431)
1. Efficient Plasma Cell Differentiation and Trafficking Require Cxcr4 Desensitization.
Biajoux V; Natt J; Freitas C; Alouche N; Sacquin A; Hemon P; Gaudin F; Fazilleau N; Espéli M; Balabanian K
Cell Rep; 2016 Sep; 17(1):193-205. PubMed ID: 27681431
[TBL] [Abstract][Full Text] [Related]
2. Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization.
Freitas C; Wittner M; Nguyen J; Rondeau V; Biajoux V; Aknin ML; Gaudin F; Beaussant-Cohen S; Bertrand Y; Bellanné-Chantelot C; Donadieu J; Bachelerie F; Espéli M; Dalloul A; Louache F; Balabanian K
J Exp Med; 2017 Jul; 214(7):2023-2040. PubMed ID: 28550161
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
4. Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome.
Mc Guire PJ; Cunningham-Rundles C; Ochs H; Diaz GA
Clin Immunol; 2010 Jun; 135(3):412-21. PubMed ID: 20226738
[TBL] [Abstract][Full Text] [Related]
5. [CXCR4 as a rheostat of humoral response].
Khamyath M; Bonaud A; Balabanian K; Espéli M
Med Sci (Paris); 2023 Jan; 39(1):23-30. PubMed ID: 36692314
[TBL] [Abstract][Full Text] [Related]
6. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome.
Bachelerie F
Dis Markers; 2010; 29(3-4):189-98. PubMed ID: 21178277
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome.
de Wit RH; Heukers R; Brink HJ; Arsova A; Maussang D; Cutolo P; Strubbe B; Vischer HF; Bachelerie F; Smit MJ
J Pharmacol Exp Ther; 2017 Oct; 363(1):35-44. PubMed ID: 28768817
[TBL] [Abstract][Full Text] [Related]
8. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.
Balabanian K; Lagane B; Pablos JL; Laurent L; Planchenault T; Verola O; Lebbe C; Kerob D; Dupuy A; Hermine O; Nicolas JF; Latger-Cannard V; Bensoussan D; Bordigoni P; Baleux F; Le Deist F; Virelizier JL; Arenzana-Seisdedos F; Bachelerie F
Blood; 2005 Mar; 105(6):2449-57. PubMed ID: 15536153
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 signaling in health and disease.
Pozzobon T; Goldoni G; Viola A; Molon B
Immunol Lett; 2016 Sep; 177():6-15. PubMed ID: 27363619
[TBL] [Abstract][Full Text] [Related]
10. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice.
Balabanian K; Brotin E; Biajoux V; Bouchet-Delbos L; Lainey E; Fenneteau O; Bonnet D; Fiette L; Emilie D; Bachelerie F
Blood; 2012 Jun; 119(24):5722-30. PubMed ID: 22438253
[TBL] [Abstract][Full Text] [Related]
11. G protein-coupled receptor kinase-3-deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses.
Tarrant TK; Billard MJ; Timoshchenko RG; McGinnis MW; Serafin DS; Foreman O; Esserman DA; Chao NJ; Lento WE; Lee DM; Patel D; Siderovski DP
J Leukoc Biol; 2013 Dec; 94(6):1243-51. PubMed ID: 23935208
[TBL] [Abstract][Full Text] [Related]
12. Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.
Alouche N; Bonaud A; Rondeau V; Hussein-Agha R; Nguyen J; Bisio V; Khamyath M; Crickx E; Setterblad N; Dulphy N; Mahevas M; McDermott DH; Murphy PM; Balabanian K; Espéli M
Blood; 2021 Jun; 137(22):3050-3063. PubMed ID: 33512437
[TBL] [Abstract][Full Text] [Related]
13. Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking.
Mayol K; Biajoux V; Marvel J; Balabanian K; Walzer T
Blood; 2011 Nov; 118(18):4863-71. PubMed ID: 21911833
[TBL] [Abstract][Full Text] [Related]
14. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse.
Kallikourdis M; Trovato AE; Anselmi F; Sarukhan A; Roselli G; Tassone L; Badolato R; Viola A
Blood; 2013 Aug; 122(5):666-73. PubMed ID: 23794067
[TBL] [Abstract][Full Text] [Related]
15. Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model.
Gao JL; Yim E; Siwicki M; Yang A; Liu Q; Azani A; Owusu-Ansah A; McDermott DH; Murphy PM
J Clin Invest; 2018 Aug; 128(8):3312-3318. PubMed ID: 29715199
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome.
Lagane B; Chow KY; Balabanian K; Levoye A; Harriague J; Planchenault T; Baleux F; Gunera-Saad N; Arenzana-Seisdedos F; Bachelerie F
Blood; 2008 Jul; 112(1):34-44. PubMed ID: 18436740
[TBL] [Abstract][Full Text] [Related]
17. WHIM syndrome: Immunopathogenesis, treatment and cure strategies.
McDermott DH; Murphy PM
Immunol Rev; 2019 Jan; 287(1):91-102. PubMed ID: 30565238
[TBL] [Abstract][Full Text] [Related]
18. Cerebellar involvement in warts Hypogammaglobulinemia immunodeficiency myelokathexis patients: neuroimaging and clinical findings.
Galli J; Pinelli L; Micheletti S; Palumbo G; Notarangelo LD; Lougaris V; Dotta L; Fazzi E; Badolato R
Orphanet J Rare Dis; 2019 Feb; 14(1):61. PubMed ID: 30819232
[TBL] [Abstract][Full Text] [Related]
19. CCR6 Defines Memory B Cell Precursors in Mouse and Human Germinal Centers, Revealing Light-Zone Location and Predominant Low Antigen Affinity.
Suan D; Kräutler NJ; Maag JLV; Butt D; Bourne K; Hermes JR; Avery DT; Young C; Statham A; Elliott M; Dinger ME; Basten A; Tangye SG; Brink R
Immunity; 2017 Dec; 47(6):1142-1153.e4. PubMed ID: 29262350
[TBL] [Abstract][Full Text] [Related]
20. [CXCR4, a therapeutic target in rare immunodeficiencies?].
Bignon A; Biajoux V; Bouchet-Delbos L; Emilie D; Lortholary O; Balabanian K
Med Sci (Paris); 2011 Apr; 27(4):391-7. PubMed ID: 21524404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
